About
About
Shield Therapeutics is a well-funded, high potential, commercial stage specialty-pharma company. We pride ourselves on providing solutions to unmet medical needs and delivering value to our shareholders.
Explore section
Our Strategy & Values

People
Lead Products
Lead Products
Shield has a rare opportunity to build an integrated, highly profitable specialty pharma business. In this section you can learn more about our lead product, and about our second asset.
Explore section
Feraccru^®
Pipeline product candidates
Investors
Investors
Shield is well positioned to become a fast growing, independent, international specialty pharmaceutical company due to the strength of its products and team, and with great thanks to all of our supportive shareholders.
Explore section
Share Price Summary

RNS News

Corporate Governance

AIM Rule 26

Video and Audio

Investor Contacts

Corporate Documents

Presentations

Advisor Contacts

Financial Calendar

Analyst Coverage
News
Events

Shield Therapeutics announces submission of a New Drug Application (NDA) for Feraccru® with the US Food and Drug Administration (FDA)

1 Oct 2018

Shield Therapeutics plc, today announces that it has received confirmation from the US FDA of its successful submission of an NDA for Feraccru®. For more details please see the press release below.

STX_NDA submission

Back to news

Shield Therapeutics announces submission of a New Drug Application (NDA) for Feraccru® with the US Food and Drug Administration (FDA)

Sign up for news